Coronavirus company news summary – FDA provides EUA for Covid-19 antigen test – Centogene and OESIS to screen for Covid-19 at schools

7 July 2020 (Last Updated July 7th, 2020 09:29)

The US Food and Drug Administration (FDA) has awarded an Emergency Use Authorization (EUA) for a Covid-19 antigen diagnostic test, the BD Veritor System for Rapid Detection of SARS-CoV-2 virus. This approval marks the second antigen test for SARS-CoV-2 antigen detection to have received EUA from FDA.

Julius Group has partnered with Noble Biomaterials for the production of reusable  antiviral/antibacterial gloves and masks. This partnership will enable Julius Group to produce PPE using Ionic+ antimicrobial technology of Noble Biomaterials. The reusable antimicrobial gloves and masks will be produced from fabric that has 99.9% pure silver which is expected to reduce the virus infectivity on soft surfaces.

Chembio Diagnostics plans to submit applications for EUA to the FDA for a revised version of the DPP COVID-19 IgM/IgG System and DPP COVID-19 Antigen System. The DPP COVID-19 IgM/IgG System is a Covid-19 point-of-care serology system while the DPP COVID-19 Antigen System is a new Covid-19 point-of-care antigen system.

Centogene has partnered with OESIS Network to carry out Covid-19 screening of schools in the US. With this partnership, RT-PCR testing will support schools to restart classes on campus in the fall and for continued screening to avoid a resurgence of Covid-19 outbreak.